Building a High-Dose-Rate Prostate Brachytherapy Program With Real-Time Ultrasound-Based Planning: Initial Safety, Quality, and Outcome Results-Reference-Cited by-同舟云学术

Building a High-Dose-Rate Prostate Brachytherapy Program With Real-Time Ultrasound-Based Planning: Initial Safety, Quality, and Outcome Results

Published:2020-05 Issue:3 Volume:5 Page:388-395
ISSN:2452-1094
Container-title:Advances in Radiation Oncology
language:en
Short-container-title:Advances in Radiation Oncology

Author:

Zhang Hong^ORCID,Kang Sohyun^ORCID,Ali Naba,Baran Andrea^ORCID,Bylund Kevin^ORCID,Gentile David,Previte Gregory,Matloubieh Ahmad,Gray Alex,Marou Nancy^ORCID

Publisher

Elsevier BV

Subject

Radiology, Nuclear Medicine and imaging,Oncology

Reference37 articles.

1. 10-Year outcomes after monitoring, surgery, or radiotherapy for localized prostate cancer;Hamdy;N Engl J Med,2016

2. Causes of death among cancer patients;Zaorsky;Ann Oncol,2017

3. The rise and fall of prostate brachytherapy: Use of brachytherapy for the treatment of localized prostate cancer in the National Cancer Data Base;Martin;Cancer,2014

4. Prostate brachytherapy case volumes by academic and nonacademic practices: Implications for future residency training;Orio;Int J Radiat Oncol Biol Phys,2016

5. Comparative analysis of prostate-specific antigen free survival outcomes for patients with low, intermediate and high risk prostate cancer treatment by radical therapy. Results from the Prostate Cancer Results Study Group;Grimm;BJU Int,2012

Cited by 3 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. High-dose-rate Brachytherapy Monotherapy in Patients With Localised Prostate Cancer: Dose Modelling and Optimisation Using Computer Algorithms;Clinical Oncology;2024-06

2. Implementation of High-Dose-Rate, CT-Based Prostate Brachytherapy in an Academic Teaching Hospital and Residency Training Program;Cureus;2022-02-22

3. Performance of an integrated multimodality image guidance and dose-planning system supporting tumor-targeted HDR brachytherapy for prostate cancer;Radiotherapy and Oncology;2022-01